Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paclitaxel dose intensity

E Reed1, R Bitton, G Sarosy

  • 1Medical Ovarian Cancer Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. reed92@helix.nih.gov

The Journal of Infusional Chemotherapy
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated assessment of the effects of PFOA exposure on hepatic transcriptome and lipid profiles in mice expressing human PPARα.

Toxicology and applied pharmacology·2025
Same author

Inferior vena cava ultrasonography before general anesthesia cannot predict arterial hypotension in patients undergoing vascular surgery.

Revista espanola de anestesiologia y reanimacion·2022
Same author

A new mechanism for void-cascade interaction from nondestructive depth-resolved atomic-scale measurements of ion irradiation-induced defects in Fe.

Science advances·2020
Same author

Multi-level Determinants of Clinic Attendance and Antiretroviral Treatment Adherence Among Fishermen Living with HIV/AIDS in Communities on Lake Victoria, Uganda.

AIDS and behavior·2018
Same author

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Microcirculatory changes during cardiac surgery with cardiopulmonary bypass.

Revista espanola de anestesiologia y reanimacion·2016
Same journal

Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma.

The Journal of infusional chemotherapy·1996
Same journal

Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.

The Journal of infusional chemotherapy·1996
Same journal

The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.

The Journal of infusional chemotherapy·1996
Same journal

The French experience with infusional 5-FU in gastric and pancreatic cancer.

The Journal of infusional chemotherapy·1996
Same journal

Drug stability and compatibility in oncology care.

The Journal of infusional chemotherapy·1996
Same journal

Options for venous access in ambulatory care: issues in selection and management.

The Journal of infusional chemotherapy·1996
See all related articles

Paclitaxel dose intensity significantly impacts treatment response in ovarian and breast cancers. Optimal results were observed at 250 mg/m2/21 days, suggesting dose intensity is crucial for effective chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Paclitaxel is a key chemotherapy agent for ovarian and breast cancers.
  • The role of dose intensity in paclitaxel's efficacy requires further investigation.

Purpose of the Study:

  • To assess the relationship between paclitaxel dose intensity and disease response in ovarian and breast cancers.
  • To identify optimal paclitaxel dosing strategies for improved clinical outcomes.

Main Methods:

  • Analysis of available Phase II clinical trial data for ovarian and breast cancers.
  • Application of Hrynuik and Levin methods to evaluate dose-response relationships.
  • Review of prospective randomized studies on paclitaxel dose intensity in ovarian cancer.

Related Experiment Videos

Main Results:

  • A statistically significant correlation between paclitaxel dose intensity and objective response was found in ovarian cancer (p=0.022) and breast cancer (p=0.004).
  • Optimal response rates were achieved with a paclitaxel dose of 250 mg/m2/21 days via 24-hour IV infusion.
  • Randomized studies in ovarian cancer showed response rates of 13.2% at 135 mg/m2/21 days and 35.9% at 250 mg/m2/21 days.

Conclusions:

  • Paclitaxel dose intensity is a critical determinant of treatment efficacy in ovarian and breast cancers.
  • A dosing strategy of 250 mg/m2/21 days is associated with optimal clinical results.
  • Cytokine support may be essential for maintaining high-dose paclitaxel intensity.